Hansoh Pharmaceutical Resubmits Aumuletinib MAA to the EMA – EGFR‑TKI Application Validated for Two Advanced NSCLC Indications After EU Market Withdrawal

Hansoh Pharmaceutical Group Company Limited (HKG: 6998) announced that the company has resubmitted its marketing authorization application (MAA) for the innovative drug aumuletinib in the European Union to the European Medicines Agency (EMA). The application was officially validated by the EMA on October 7 for two indications in advanced non‑small cell lung cancer (NSCLC) — the resubmission following the September 27, 2026 withdrawal of almonertinib from the EU market after a lawsuit filed by AstraZeneca over referenced data protection.

Regulatory Milestone

Drug Profile & Indication Context

• Molecule: Aumuletinib, an innovative epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) from Hansoh Pharmaceutical.
• Target Population – First Line: Adult patients with advanced NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations — the two classic activating EGFR mutations that define first-line TKI eligibility.
• Target Population – T790M: Adult patients with advanced NSCLC with positive EGFR T790M mutation, the canonical resistance mutation arising after earlier-generation EGFR‑TKI therapy.
• Dual-Indication Strategy: The validated application seeks both a first-line and a post-resistance setting, mirroring the label structure established in the third-generation EGFR‑TKI class.

Regulatory Background – The Withdrawal and Resubmission

• AstraZeneca Lawsuit: Almonertinib was withdrawn from the EU market on September 27, 2026 following a lawsuit filed by AstraZeneca.
• Data Protection Issue: The withdrawal occurred because data submitted in the original application referenced Tagrisso (osimertinib) data that were still under regulatory data protection at the time — a breach of the EU’s period of data exclusivity granted to originator products.
• Strategic Response: Hansoh’s resubmission, validated by the EMA within days of the withdrawal taking effect, indicates a restructured application designed to proceed without reliance on protected reference data.
• Validation Meaning: EMA validation confirms the application is complete and admissible, starting the formal review clock toward a CHMP opinion; review timelines were not disclosed.

Market Impact & Outlook

• EU Market Re-Entry Bid: The resubmission positions aumuletinib to re-contest the European EGFR‑mutant NSCLC market, where third-generation TKIs anchor both first-line and T790M treatment.
• Data Exclusivity Precedent: The AstraZeneca action underscores the enforceability of EU regulatory data protection and the litigation risk faced by follow-on applicants referencing protected originator data.
• Competitive Landscape: The EGFR‑TKI class in the EU is led by osimertinib (Tagrisso), with additional third-generation and combination approaches competing; aumuletinib’s differentiation and pricing will shape uptake upon any future approval.
• Hansoh’s Globalization Strategy: Persisting with the EU pathway after withdrawal reflects the company’s commitment to international expansion of its innovative oncology portfolio beyond China.
• Next Steps: EMA review of the validated application; a CHMP opinion timeline and any further litigation developments were not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Hansoh Pharmaceutical’s resubmitted aumuletinib MAA in the European Union, including the EMA review process and potential authorization for the two NSCLC indications. Validation does not guarantee approval. Actual results may differ due to risks including regulatory review outcomes, data-protection litigation, clinical evidence requirements, and competitive dynamics.-Fineline Info & Tech